Eyenovia Reports Q1 Loss and Pursues Merger with Betaliq

Introduction

EYENOVIA INC (NASDAQ: EYEN) is an ophthalmic technology company headquartered in New York, New York. Since its founding in 2014, the firm has developed the proprietary Optejet® topical medication dispensing platform and brought to market FDA-approved products including a clobetasol propionate suspension (0.05%) for post-surgical inflammation and MydCombi® for pupil dilation. As of June 18, 2025, EYEN trades on the NASDAQ under the ticker “EYEN” at USD 4.3501, reflecting a 37.59 percent decline on significant trading volume.

Corporate Structure

Eyenovia employs between 51 and 200 professionals across research, development, regulatory affairs, and commercial operations. The company’s leadership team includes executives with experience in ophthalmology, pharmaceutical manufacturing, and medical device commercialization. In addition to U.S. operations, Eyenovia maintains license partnerships—most notably with Arctic Vision in China and Korea—to support international product distribution.

Recent Developments and News

On May 19, 2025, Eyenovia issued its first quarter 2025 financial results and provided updates on two major initiatives:

• Potential merger with Betaliq: Eyenovia and Betaliq extended their binding exclusivity period to June 7, 2025, under a letter of intent. The proposed deal would combine Eyenovia’s Optejet® platform with Betaliq’s Eyesol® water-free delivery technology for glaucoma.
• Optejet user-filled device (UFD): The company remains on track to file for U.S. device regulatory approval in September 2025, positioning Optejet UFD for commercialization either directly to consumers or through eye care practitioners.

In two amendments to Schedule 13D filings, dated June 3 and June 13, 2025, Avenue Venture Opportunities Fund, L.P. and Avenue Venture Opportunities Fund II, L.P. disclosed combined direct ownership of up to 9.99 percent of shares outstanding, plus convertible loans totaling 5,565,931 shares issuable.

On June 5, 2025, an 8-K filing announced a debt restructuring agreement with Avenue Capital, deferring certain repayment obligations to October 2025.

Financial and Strategic Analysis

For the quarter ended March 31, 2025, Eyenovia reported a net loss of USD 3.5 million (USD 1.59 per share), compared to a net loss of USD 10.9 million (USD 18.75 per share) in Q1 2024. Key expense reductions year-over-year included:

• Research & development: USD 0.7 million, down 85 percent from USD 4.4 million.
• General & administrative: USD 2.4 million, down 35 percent from USD 3.6 million.
• Total operating expenses: USD 3.0 million, down 70 percent from USD 10.1 million.

As of March 31, 2025, unrestricted cash and equivalents stood at USD 3.9 million, up from USD 2.1 million at December 31, 2024. The debt restructuring agreement with Avenue Capital improved liquidity by deferring certain repayments until October 2025.

According to Yahoo Finance metrics (as of June 16, 2025), Eyenovia’s market capitalization is approximately USD 7.03 million, with trailing twelve-month revenue of USD 67,060 and net income of -USD 42.38 million. Valuation multiples indicate the early-stage nature of the business: price/sales of 44.92 and enterprise value/revenue of 212.42.

Market Position and Industry Context

Eyenovia operates in the ophthalmic drug-device market, targeting chronic front-of-the-eye conditions such as post-surgical inflammation, presbyopia, and pediatric progressive myopia. Its Optejet® platform seeks to differentiate on ease of use, safety, and compliance relative to standard eyedrops. Key competitors include major pharmaceutical and medical technology companies such as Alcon, Novartis/Sandoz, and Santen, as well as specialty players in ocular drug delivery. With a limited commercial portfolio and strategic partnerships in Asia, Eyenovia remains in an early-stage position, reliant on regulatory approvals, product launches, and potential merger outcomes to drive revenue growth.

tl;dr

• On May 19, 2025, Eyenovia reported Q1 net loss of USD 3.5 million and reduced cash burn by 70 percent year-over-year, with USD 3.9 million in unrestricted cash at quarter end.
• Negotiations for a merger with Betaliq continued through June 7, 2025, aiming to combine Optejet® and Eyesol® technologies.
• A U.S. regulatory filing for the Optejet UFD is anticipated in September 2025.
• Convertible loans held by Avenue Capital funds could issue 5.6 million new shares, indicating potential dilution; debt repayment deferral extends runway to October 2025.
• Important upcoming events include the merger decision, device approval in September, and financial performance updates into Q3 2025.